Table 2.
Granted Patents/Patent Applications for Hepatitis B Vaccines.
| Patent Application Number | The Assignee of the Grant | Claim | Publication Date |
|---|---|---|---|
| CN114210310A | Wuhan Ruyi Medical Instr Co., Ltd., China | An immunoadsorption material for the hepatitis B virus and HBsAg is provided by the invention, together with a method for its production and use. A hepatitis B virus antibody solution and agarose microspheres are coupled during the coupling reaction process of aldehyde crosslinking, according to the method. To effectively lower the levels of the hepatitis B virus and HBsAg in a patient’s blood, the immunoadsorption material can directly, effectively, and selectively adsorb the hepatitis B virus and HBsAg from plasma. | 22 November 2022 |
| EP3710049A4 | University of Washington | HBV PreS1 and/or PreS2, as well as S-HBsAg sections of the HBV envelope protein, are used as a therapeutic vaccine for the disease. | 5 January 2022 |
| CN113544148A | Humabs BioMed, Bellinzona, Switzerland | The antibodies and antigen-binding fragments described in the current disclosure bind to the antigenic loop region of the hepatitis B surface antigen (HBsAg) and neutralize both hepatitis B and hepatitis D virus infection (HDV). The disclosure also includes information on the epitopes that these antibodies and their antigen-binding fragments bind to, fusion proteins that contain the antigen-binding fragments, the nucleic acids that code for these antibodies and antibody fragments, and the cells that produce them. | 22 October 2021 |
| US10793866B2 | Dr. LifeSciences Group Limited | This invention disclosed a method to create an edible vaccine based on an expression platform for the N-terminal yeast surface display that would protect and treat people against infection with the hepatitis B virus. | 6 October 2020 |
| US10653772B2 | Tianjin Hemu Jianmin Biotechnology Co., Ltd. | A hepatitis B therapeutic vaccination based on inactivated entire recombinant Hansenula polymorpha cells producing HBsAg is being developed. The intracellular level of expression of HBsAg in the recombinant Hansenula polymorpha cells is 6–10 g HBsAg per 108 cells. | 19 May 2020 |
| CN110898219A | Institute of Biophysics, Chinese Academy of Sciences | The hepatitis B virus surface antigen peptide and ferritin are linked by a linker. The connector is flexible while the ferritin is bacterial, and the hepatitis B virus surface antigen peptide segment comprises a preS1 peptide segment. | 24 March 2020 |
| WO2019013361A1 | Beacle Inc., Kagoshima University | This hepatitis B vaccine comprises formed surface antigen particles in which only hepatitis B virus L proteins or mutants of said L proteins are pooled on the lipid membrane. | 17 January 2019 |
| US10058606B2 | TheVax Genetics Vaccine Co., Ltd. | In this innovative vaccine, the following components are used: (i) a hepatitis B x antigen mutant with no amino acid domain, (ii) a domain for protein transduction, and (iii) a domain that binds to either CD91 receptors or antigen-presenting cells (APCs). A linker, a translocation peptide, and a T cell sensitivity signal-transducing peptide make up the antigen transduction domain of this fusion polypeptide. | 28 August 2018 |
| CN106928372A | Application filed by Peking University Shenzhen Graduate School | This invention relates to a recombinant hepatitis B antigen which is prepared by linking the hepatitis B virus preS region, the influenza virus hemagglutinin signal peptide region, the influenza virus transmembrane region, and the intracellular region and carrying out expression. It has the potential to be transformed into a novel preventative and therapeutic hepatitis B vaccine in medical science. |
7 July 2017 |
| CN106701825A | Institute of Biophysics of Chinese Academy of Sciences | This vaccine includes a nucleic acid sequence formed through introducing s-HBsAg and the immune co-stimulator molecule LIGHT to the type-5 adenovirus vector. The vaccine has a significant therapeutic effect on hepatitis B. | 24 May 2017 |
| CN106421774A | Institute of Biophysics of Chinese Academy of Sciences | The vaccine comprises a hepatitis B virus envelope protein from the preS1 region and can effectively prevent HBV from infecting the host, and has a therapeutic effect on chronic hepatitis B virus infection; its effect is significantly better than the existing traditional HBV vaccine. | 22 February 2017 |
| CN105727280A | Tianjin Jianmin harmony Biotechnology Co., Ltd. | This is a hepatitis B therapeutic vaccine based on heat-inactivated all-recombinant Hansen USA cells capable of expression of HBsAg. The vaccine is based on the Hansenula expression system platform; by releasing IFNγ in liver cells with HBsAg-specific CTLs, it targets cells infected with HBV. | 6 July 2016 |
| CN105061591A | Second Military Medical University (SMMU) | This invention provides an anti-hepatitis B virus surface antigen fully humanized antibody, A3D5, and the gene encoding the antibody. The A3D5 antibody is capable of specifically binding to the HBsAg protein, has better HBV-neutralizing activity, and may prevent the process of infection-related hepatitis, cirrhosis, and liver cancer mediated by HBV. | 18 November 2015 |
| CN104043120A | Simcere Pharmaceutical pharmaceutical company |
The immunogenic activity of hepatitis B core and surface antigens was utilized to treat HBV infection and HBV-mediated illnesses, and a method for treating HBV infection is included in the sulpho-oligodeoxynucleotide. | 17 September 2014 |
| CN111363728A | Wuhan University, China | The influenza A virus is taken as a vector, the hepatitis B virus gene is integrated into the genome of the influenza virus through reverse genetics technology, and the recombinant influenza virus can be stably passaged in a host cell or a chicken embryo. | 18 June 2014 |
| CN103566369A | Cancer Hospital and Institute, Chinese Academy of Medical Sciences, CAMS, and Peking Union Medical College, PUMC. | This invention reports a hepatitis B vaccine that induces the body to generate specific immunity under a chronic hepatitis B virus infection state. This inventive hepatitis B vaccine contains Toll-like receptor agonists as an immune enhancer. | 12 February 2014 |
| CN102949717A | China center for diseases control and prevention, National Institute for Virology, Beijing, China | This is a genetic engineering vaccine that comprises the hepatitis B virus surface antigen, an aluminum hydroxide adjuvant, and a polyinosinic acid-polycytidylic acid adjuvant. The vaccine can be used for treating chronic hepatitis B. | 6 March 2013 |
| CN102199217A | Third Military Medical University (TMMU). Chongqing, China. | This fusion protein is obtained by inserting hepatitis B virus multi-epitope fusion peptide formed by serially connecting HBsAg313-321, HBsAg335-343, Pol150-159, Pol455-463, and Padre epitopes through connecting peptide between the amino acid at the 78th position and the amino acid at the 79th position of a hepatitis B virus core. The obtained fusion protein has strong immunogenicity and therapeutic effects on hepatitis B infection. | 28 September 2011 |
| CN101942013A | Third Military Medical University (TMMU). Chongqing, China. | This innovation offers fresh approaches and techniques for the creation of a potent therapeutic vaccine against hepatitis B and has the potential to reduce immune tolerance to the disease, restore cell-mediated immune function, and effectively inhibit and eradicate the hepatitis B virus. | 12 January 2011 |
| CN101618211A | Zhuhai Lianbang Pharmaceutical Co., Ltd., China | This hepatitis B polypeptide vaccine contains polypeptides that can stimulate a CTL reaction, and has a polypeptide sequence that contains one mutational amino-acid residue with the mutation positioned at an N-terminal end or a C-terminal end of the peptide segment. The vaccine contains one or more types of polypeptides and is used for treating chronic hepatitis B infection. | 6 January 2010 |